Compare Stocks: TRIB, BEAT, NSPR, and PAVM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAT HeartBeam	$0.55	$0.44	$0.36 ▼ $4.00	$30.99M	-0.84	22.68 million shs	1.57 million shs
NSPR InspireMD	$0.45	$0.66	$0.43 ▼ $2.40	$20.92M	0.84	152,393 shs	478,661 shs
PAVM PAVmed	$1.95	$3.57	$1.84 ▼ $28.44	$15.59M	0.69	11,477 shs	4,746 shs
TRIB Trinity Biotech	$6.42 +2.5%	$7.69	$5.01 ▼ $52.50	$5.20M	0.77	15,682 shs	6,667 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAT HeartBeam	0.00%	+39.84%	+26.55%	+11.83%	-70.04%
NSPR InspireMD	0.00%	+0.16%	-27.71%	-33.92%	-79.64%
PAVM PAVmed	0.00%	-10.14%	-32.06%	-64.55%	-84.84%
TRIB Trinity Biotech	0.00%	-12.08%	+12.79%	-42.34%	-78.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAT HeartBeam	$0.55	$0.44	$0.36 ▼ $4.00	$30.99M	-0.84	22.68 million shs	1.57 million shs
NSPR InspireMD	$0.45	$0.66	$0.43 ▼ $2.40	$20.92M	0.84	152,393 shs	478,661 shs
PAVM PAVmed	$1.95	$3.57	$1.84 ▼ $28.44	$15.59M	0.69	11,477 shs	4,746 shs
TRIB Trinity Biotech	$6.42 +2.5%	$7.69	$5.01 ▼ $52.50	$5.20M	0.77	15,682 shs	6,667 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAT HeartBeam	0.00%	+39.84%	+26.55%	+11.83%	-70.04%
NSPR InspireMD	0.00%	+0.16%	-27.71%	-33.92%	-79.64%
PAVM PAVmed	0.00%	-10.14%	-32.06%	-64.55%	-84.84%
TRIB Trinity Biotech	0.00%	-12.08%	+12.79%	-42.34%	-78.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAT HeartBeam	2.50	Moderate Buy	$4.00	627.27% Upside
NSPR InspireMD	3.00	Buy	$4.50	900.00% Upside
PAVM PAVmed	2.00	Hold	$56.00	2,771.79% Upside
TRIB Trinity Biotech	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest TRIB, BEAT, NSPR, and PAVM Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/30/2026	BEAT HeartBeam	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/6/2026	BEAT HeartBeam	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
9/29/2026	BEAT HeartBeam	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/22/2026	BEAT HeartBeam	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral
9/4/2026	TRIB Trinity Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	TRIB Trinity Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	PAVM PAVmed	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D) ➝ Sell (E+)
8/5/2026	TRIB Trinity Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 11/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAT HeartBeam	N/A	N/A	N/A	N/A	$0.06 per share	N/A
NSPR InspireMD	$10.84M	1.93	N/A	N/A	$1.83 per share	0.25
PAVM PAVmed	$112K	139.22	N/A	N/A	($2.42) per share	-0.81
TRIB Trinity Biotech	$43.78M	0.12	N/A	N/A	($601.80) per share	-0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAT HeartBeam	-$21.01M	-$0.51	N/A	N/A	N/A	N/A	-686.78%	-348.65%	11/12/2026 (Estimated)
NSPR InspireMD	-$19.92M	-$0.64	N/A	N/A	N/A	-413.96%	-69.42%	-57.68%	N/A
PAVM PAVmed	$400K	-$16.05	N/A	N/A	N/A	-10,794.64%	-126.43%	-25.49%	11/13/2026 (Estimated)
TRIB Trinity Biotech	-$37.38M	-$44.26	N/A	N/A	N/A	-70.06%	N/A	-32.13%	12/10/2026 (Estimated)

Latest TRIB, BEAT, NSPR, and PAVM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	PAVM PAVmed	-$0.63	N/A	N/A	N/A	$0.03 million	N/A
11/12/2026	Q3 2026	BEAT HeartBeam	-$0.09	N/A	N/A	N/A	$0.08 million	N/A
8/13/2026	Q2 2026	BEAT HeartBeam	-$0.0860	-$0.10	-$0.0140	-$0.10	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAT HeartBeam	N/A	N/A	N/A	N/A	N/A
NSPR InspireMD	N/A	N/A	N/A	N/A	N/A
PAVM PAVmed	N/A	N/A	N/A	N/A	N/A
TRIB Trinity Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAT HeartBeam	N/A	3.66	3.61
NSPR InspireMD	N/A	6.39	6.05
PAVM PAVmed	0.98	1.19	1.19
TRIB Trinity Biotech	N/A	0.22	0.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAT HeartBeam	7.77%
NSPR InspireMD	44.78%
PAVM PAVmed	19.93%
TRIB Trinity Biotech	78.97%

Insider Ownership

Company	Insider Ownership
BEAT HeartBeam	17.95%
NSPR InspireMD	24.98%
PAVM PAVmed	13.40%
TRIB Trinity Biotech	8.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAT HeartBeam	1,700	56.35 million	46.23 million	Not Optionable
NSPR InspireMD	127	46.49 million	18.33 million	Optionable
PAVM PAVmed	41	8.00 million	6.93 million	No Data
TRIB Trinity Biotech	287	810,000	746,000	Optionable

TRIB, BEAT, NSPR, and PAVM Headlines

Recent News About These Companies

Trinity Biotech PLC (NASDAQ:TRIB) Sees Large Growth in Short Interest

3 hours ago | americanbankingnews.com

Trinity Biotech stock trades after hours on Nasdaq

October 30 at 9:22 PM | ad-hoc-news.deA

Trinovium, filiale de Trinity Biotech plc, signe un contrat de fourniture de solutions de refroidissement liquide avancées pour les infrastructures de centres de données IA ...

September 9, 2026 | zonebourse.comZ

Trinity Biotech Signs Contract With Red Team Investments For AI Data Center Cooling Solutions

September 9, 2026 | rttnews.com

Trinity Biotech’s Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure

September 9, 2026 | finance.yahoo.com

Trinity Biotech's Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure

September 9, 2026 | globenewswire.com

Trinity Issues Updates On Diagnostics Launch; Plans To Regain Nasdaq Compliance By Feb '27

August 31, 2026 | rttnews.com

Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update

August 28, 2026 | globenewswire.com

Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure

August 17, 2026 | finance.yahoo.com

Trinity Biotech's Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure

August 17, 2026 | globenewswire.com

Trinity Biotech plc (TRIB) Stock: Jumps as Perceptive Advisors Backs $7M Investment and Nasdaq Compliance Is Restored

August 14, 2026 | blockonomi.com

Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement

August 14, 2026 | globenewswire.com

Cours Trinity Biotech plc

July 25, 2026 | zonebourse.comZ

Trinity Biotech plc: Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology

July 22, 2026 | finanznachrichten.de

Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology

July 22, 2026 | globenewswire.com

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change

July 22, 2026 | globenewswire.com

New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring

July 2, 2026 | globenewswire.com

Trinity Biotech plc: Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville

June 30, 2026 | finanznachrichten.de

Trinity Biotech’s Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling

June 30, 2026 | finance.yahoo.com

Trinity Biotech's Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling

June 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TRIB, BEAT, NSPR, and PAVM Company Descriptions

HeartBeam NASDAQ:BEAT

$0.55 0.00 (0.00%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$0.56 +0.01 (+1.45%)

As of 06:36 AM Eastern

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

InspireMD NYSE:NSPR

$0.45 0.00 (0.00%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$0.47 +0.02 (+3.56%)

As of 10/30/2026 07:46 PM Eastern

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

PAVmed NASDAQ:PAVM

$1.95 0.00 (0.00%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$1.93 -0.02 (-1.13%)

As of 06:03 AM Eastern

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Trinity Biotech NASDAQ:TRIB

$6.42 +0.16 (+2.52%)

Closing price 10/30/2026 03:59 PM Eastern

Extended Trading

$6.51 +0.09 (+1.43%)

As of 04:00 AM Eastern

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRIB, BEAT, NSPR, and PAVM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRIB, BEAT, NSPR, and PAVM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRIB, BEAT, NSPR, and PAVM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TRIB, BEAT, NSPR, and PAVM Company Descriptions

HeartBeam NASDAQ:BEAT

InspireMD NYSE:NSPR

PAVmed NASDAQ:PAVM

Trinity Biotech NASDAQ:TRIB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRIB, BEAT, NSPR, and PAVM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRIB, BEAT, NSPR, and PAVM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRIB, BEAT, NSPR, and PAVM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TRIB, BEAT, NSPR, and PAVM Company Descriptions

HeartBeam NASDAQ:BEAT

InspireMD NYSE:NSPR

PAVmed NASDAQ:PAVM

Trinity Biotech NASDAQ:TRIB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools